Exozymes CCO Damien Perriman sells $19,426 in stock

Damien Alan Perriman, Chief Commercial Officer at EXOZYMES INC. (NASDAQ:EXOZ), sold 3,729 shares of common stock on October 12, 2026, for a total value of $19,426. The shares were sold at prices ranging from $5.15 to $5.25 per share, with a weighted average price of $5.2096. Since the sale, EXOZ shares have declined to $3.75, trading near the 52-week low of $3.71. According to InvestingPro analysis, the stock appears undervalued at current levels, with Fair Value estimates suggesting upside potential. For investors seeking deeper insights, EXOZ is among 1,400+ US equities covered by comprehensive Pro Research Reports.

This disposition followed the conversion of 3,922 restricted stock units (RSUs) into common stock on October 9, 2026. These RSUs convert on a one-for-one basis, and no consideration was paid by Mr. Perriman upon conversion. The original grant of 62,759 restricted stock units occurred on April 1, 2026, vesting periodically.

The sale of shares was undertaken to cover tax withholding obligations associated with the vesting of the restricted stock units. Following these transactions, Mr. Perriman directly holds 28,692 shares of EXOZYMES common stock and 39,225 restricted stock units.

In other recent news, eXoZymes Inc. reported a net loss of $2.88 million for the second quarter of 2026. Despite being a pre-revenue company, eXoZymes is advancing toward commercialization with its lead product, NCT, which has shown a 10x productivity improvement. The company ended the quarter with $5.65 million in cash and indicated that it expects to have sufficient liquidity to fund operations through the end of 2026. In related developments, eXoZymes announced its 2026 annual meeting of shareholders will be held on November 13, 2026, with the record date set for September 15, 2026. Shareholders of record as of this date will be eligible to vote at the meeting. These recent developments highlight eXoZymes’ ongoing efforts in product development and corporate governance.